HUGE - FSD Pharma engages Tekkfund to help with business development strategies

FSD Pharma (NASDAQ:HUGE) said that on April 15 it signed a contract with Tekkfund Capital (TCC) for services to structure and assist with certain business development strategies. Under the agreement, the company said it will pay TCC a monthly fee of C$12.5K plus HST; and issue, on a monthly basis, 7K class B subordinate voting shares to TCC for the duration of the agreement. The agreement has an initial term of 2 years and may be extended by mutual consent. In addition, the company noted that on March 9, it issued 30K class B subordinate voting shares to Crystal Research Associates for preparing a research report conducted by Crystal as previously disclosed in a March 15 press release.

For further details see:

FSD Pharma engages Tekkfund to help with business development strategies